Long Progression-Free Survivors on Tarceva
Learner
Member Posts: 1
Tarceva has been shown to extend the progression-free survival time and improve the quality of life of many advanced lung cancer patients, especially for those who with positive EGFR. However, the information regarding its long-term survival benefit is still very limited. I have posted threads to seek this information, for example at http://www.inspire.com/groups/lung-cancer-survivors/discussion/ned-on-tarceva-1/ and http://cancergrace.org/forums/index.php/topic,8426.msg94341.html#msg94341. Although there were not many responses, those responded did expand my scope, and I appreciate them. Let me summarize what I have learned so far.
Most reports from clinical trials on TKI (tarceva or irresa) have focused on progression free survival probability (PFS). The median time of PFS (the time half of the patients have progressed) for positive EGFR on TKI ranged from 9 to 15 months. Some reports did include the overall survival probability (OS). However, OS is not a real measure of the long-term benefit, because patients did receive other treatments after progression. In my opinion, a more meaningful long survival time is how long a person can stay free from progression. Most trials were cut off once meaningful PFS data were obtained. The only useful information one can get for this purpose is the percentage of patients who were still progression free at the cut-off time. For example, the CALGB 30406 study showed that about 20% of the positive EGFR patients remained progression free at the 42th month, while the NEJ002 study showed that 10% the Iressa arm were FPS at 27th month. The above information indicated that a patient free from progression for 2 years (twice the median) is a long progression-free survivor (LPFS). Unfortunately, previous trials have not reported the follow-ups of those who survived after the trials, so information is lacking regarding the fate of those LPFS.
In an effort to gain more information about LPFS, I have collected information from the web sites and from friends. Since tarceva was only approved as a second-line therapy in 2005 and as a first line in 2011, there are not many LPFS cases on tarceva as the first-line treatment. I have focused on advanced lc patients who claimed tarceva as an important contributor to their LPFS. In the following examples I will use NED to describe the cases of ‘no evidence of disease’, or ‘free of cancer’, or ‘full remission’, because they all mean the same thing to me. Below is a summary of my finding:
I have information about six (6) individuals who have LPFS exceeding 5 years up to now, four (4) of them have claimed NED.
In addition, indirect sources have added 10 to 12 cases with LPFS for more than 5 years. However, their current status is not clear.
I also have information about fifteen LPFS who have been in treatment for less than 5 years. Four (4) of them are in NED.
In addition to the above, unfortunately five (5) individuals have progressed after passing the two-year mark.
It is also good to know that three (3) individuals have gained NED on tarceva in less than two years.
These examples do not have statistical implication, because I do not know the total samples. They are intended to give encouragement to tarceva users. I hope that the CSN will expand the scope in this post.
Most reports from clinical trials on TKI (tarceva or irresa) have focused on progression free survival probability (PFS). The median time of PFS (the time half of the patients have progressed) for positive EGFR on TKI ranged from 9 to 15 months. Some reports did include the overall survival probability (OS). However, OS is not a real measure of the long-term benefit, because patients did receive other treatments after progression. In my opinion, a more meaningful long survival time is how long a person can stay free from progression. Most trials were cut off once meaningful PFS data were obtained. The only useful information one can get for this purpose is the percentage of patients who were still progression free at the cut-off time. For example, the CALGB 30406 study showed that about 20% of the positive EGFR patients remained progression free at the 42th month, while the NEJ002 study showed that 10% the Iressa arm were FPS at 27th month. The above information indicated that a patient free from progression for 2 years (twice the median) is a long progression-free survivor (LPFS). Unfortunately, previous trials have not reported the follow-ups of those who survived after the trials, so information is lacking regarding the fate of those LPFS.
In an effort to gain more information about LPFS, I have collected information from the web sites and from friends. Since tarceva was only approved as a second-line therapy in 2005 and as a first line in 2011, there are not many LPFS cases on tarceva as the first-line treatment. I have focused on advanced lc patients who claimed tarceva as an important contributor to their LPFS. In the following examples I will use NED to describe the cases of ‘no evidence of disease’, or ‘free of cancer’, or ‘full remission’, because they all mean the same thing to me. Below is a summary of my finding:
I have information about six (6) individuals who have LPFS exceeding 5 years up to now, four (4) of them have claimed NED.
In addition, indirect sources have added 10 to 12 cases with LPFS for more than 5 years. However, their current status is not clear.
I also have information about fifteen LPFS who have been in treatment for less than 5 years. Four (4) of them are in NED.
In addition to the above, unfortunately five (5) individuals have progressed after passing the two-year mark.
It is also good to know that three (3) individuals have gained NED on tarceva in less than two years.
These examples do not have statistical implication, because I do not know the total samples. They are intended to give encouragement to tarceva users. I hope that the CSN will expand the scope in this post.
0
Comments
-
My Mum
Hi, it was good to read all of your post. My Mum is starting Tarceva on Monday following unsuccessful chemo. She has a T4 Tumour in one lung, deposits in her other plus nodes on her chest, pelvic bone and a large lump just sitting on her side. She has had radiotherapy on her pelvic bone for pain relief only and on her side to try to reduce it. So far, she has only received bad news at each appointment and is currently at a very low ebb. The chemo absolutely wiped her out even though she only had 2 sessions, they stopped it as it had not shrunk the original tumour, another lump had appeared and it had made her so ill. My Dad and I are pinning all our hopes on Tarceva as my Mum seems to be going downhill. She hasn't had any treatment other than radiotherapy for 6 weeks now and the change in her is quite drastic. I see her at least 2-3 times a week and we speak at least twice each day, so I know the effect the cancer is having. I'm terrified of losing her and although my Dad and I never speak of it, I know he feels the same if not worse. My Mum has 3 children and 6 grandchildren, 2 of which are mine and are only 3 years old (April) and 8 months old. I will be devastated if they don't have memories of their Nana as she is the most amazing woman and I know it breaks her heart to think she will not see them grow. I'm looking for some hope............... I seem to be posting alot but not getting many replies, but it does help to at least get some of my feelings out, so please forgive me if I keep repeating the same thing.0
Discussion Boards
- All Discussion Boards
- 6 CSN Information
- 6 Welcome to CSN
- 121.8K Cancer specific
- 2.8K Anal Cancer
- 446 Bladder Cancer
- 309 Bone Cancers
- 1.6K Brain Cancer
- 28.5K Breast Cancer
- 397 Childhood Cancers
- 27.9K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.2K Gynecological Cancers (other than ovarian and uterine)
- 13K Head and Neck Cancer
- 6.4K Kidney Cancer
- 671 Leukemia
- 792 Liver Cancer
- 4.1K Lung Cancer
- 5.1K Lymphoma (Hodgkin and Non-Hodgkin)
- 237 Multiple Myeloma
- 7.1K Ovarian Cancer
- 61 Pancreatic Cancer
- 487 Peritoneal Cancer
- 5.5K Prostate Cancer
- 1.2K Rare and Other Cancers
- 539 Sarcoma
- 730 Skin Cancer
- 653 Stomach Cancer
- 191 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.8K Uterine/Endometrial Cancer
- 6.3K Lifestyle Discussion Boards